A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

BACKGROUND: BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the association between pembrolizumab and carboplatin could be active in BRCA-related mBC. PATIENTS AND METHODS: In this phase II Simon’s d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortesi, L., Venturelli, M., Cortesi, G., Caggia, F., Toss, A., Barbieri, E., De Giorgi, U., Guarneri, V., Musolino, A., De Matteis, E., Zambelli, A., Bisagni, G., Dominici, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163155/
https://www.ncbi.nlm.nih.gov/pubmed/37028000
http://dx.doi.org/10.1016/j.esmoop.2023.101207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163155/
https://www.ncbi.nlm.nih.gov/pubmed/37028000
http://dx.doi.org/10.1016/j.esmoop.2023.101207

Ejemplares similares